Bris­tol My­ers Squibb out­races the pack to a late-stage tri­al win for its LAG-3/PD-1 an­ti­body com­bo in melanoma

As one of bio­phar­ma’s many shots on goal at new check­point in­hibitors, the LAG-3 class has, pun in­tend­ed, lagged be­hind with lit­tle mean­ing­ful da­ta to show. But a num­ber of big drug­mak­ers have rea­son to be­lieve that a LAG-3 and PD-1 com­bo could solve the puz­zle in on­col­o­gy — and new da­ta from Bris­tol My­ers Squibb help that case.

A com­bi­na­tion of an­ti­body re­latlimab and PD-1 in­hibitor Op­di­vo sig­nif­i­cant­ly ex­tend­ed pro­gres­sion-free sur­vival over Op­di­vo alone in first-line melanoma pa­tients whose tu­mors are ei­ther metasta­t­ic or un­able to be sur­gi­cal­ly re­moved, ac­cord­ing to topline da­ta from the Phase III REL­A­TIV­I­TY-047 study re­leased Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER